Detalhe da pesquisa
1.
Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Virol J
; 21(1): 68, 2024 03 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38509536